The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Does your doctor know all the potential side effects of your new prescription?

“One of the unfortunate realities involving new drugs is that many of them are found to have side effects, some life-threatening, that no one was aware of at the time of their approval by the FDA.”

That quote begins an article written by two M.D.s from the University of Washington School of Medicine. The article, entitled “Recently Discovered Side Effects of New Medications,” appeared in the journal Emergency Medicine, presumably because these side effects could send you to your local emergency room. But as the article points out, the ER doctors may not know that your symptoms are a side effect of a medication you’re taking.

New drugs have been coming out so quickly and in such great numbers, it’s difficult to keep up with the information. In addition, doctors and pharmacists are flooded with post-approval reports detailing updates and changes. “Educating health care providers about these newly discovered side effects is always difficult,” admit the article’s authors.

And the FDA is not required to inform the public of post-approval reports – they rely on doctors and pharmacists to get the word out. But if doctors can’t even keep up with all the reports, how can we assume that they will inform each and every one of their affected patients?

Let’s face it – YOU are the one at risk from these newly approved drugs, not your doctor or pharmacist. And you deserve access to this information as it is uncovered so you can identify symptoms and assess your risk.

That’s why I thought it was so important to bring this information directly to you — and why we will continue to monitor this issue on a regular basis.
There isn’t room here to list all the side effects of all the drugs listed in the article. (There are seven specific drugs or classes of drugs in all – all approved by the FDA in the last five years.) In this e-Alert, I’ll tell you about a few of the most common drugs on the list, and the side effects and contraindications to look for. But don’t stop there – follow the link at the end of the e-Alert to view the entire list from the article, to make sure you and your family are protected.

Angina, altered mental state can be side effects of heart medication 

An anti-platelet agent called clopidogrel (brand name: Plavix) is often prescribed to patients who have recently had a heart attack or stroke, or to those who have a history of peripheral vascular disease. New evidence shows it may cause a serious disease called thrombocytopenic purpura (TTP). Patients with TTP experience dangerously low platelet levels, kidney failure, fever, and altered mental status. TTP is also associated with a condition called microangiopathic hemolytic anemia, in which fragments of damaged red blood cells are found in the blood stream. Studies leading up to clopidogrel’s approval in 1997 did not show any increased risk of TTP, even though related drugs were known to cause the condition. But since clopidogrel’s approval, new evidence has emerged that shows the drug may cause TTP, even after only a few weeks of treatment. The article recommends that patients taking clopidogrel be closely monitored for signs of TTP. Common symptoms like angina or altered mental status may be red flags, and should not be dismissed as normal manifestations of cardiovascular disease or age.

 

Drug for RA and Crohn’s may cause MS

Etenercept (brand name Enbrel) was approved in October of 1998 to treat the symptoms of rheumatoid arthritis (RA). It has also been used to treat Crohn’s disease, although it’s not approved by the FDA for that use. It is usually injected under the skin twice a week. Originally patients were warned about the possibility of allergic reactions at the injection site and minor infections. But since its approval, the FDA has revised its recommendations, advising doctors not to prescribe etenercept to any patient with an active infection. Also, recent reports have associated etenercept with disorders of the central nervous system, like multiple sclerosis (MS) and Guillain-Barre syndrome, a condition characterized by temporary loss of movement and sensation. These disorders are both linked with the destruction of the myelin sheaths that surround and protect the nerves.

 

Antibiotics can cause tendons to rupture 

Quinolones, the class of antibiotics that includes Cipro, Norfloxacin, and Floxin, is often used to treat bacterial infections. While they are generally regarded as safe, drugs in this family showed some side effects even at the time of approval. There is some evidence that the quinolones can cause agitation, confusion, and delirium, particularly in elderly patients. They are also known to increase sun sensitivity, even up to three weeks after the medication is discontinued. The quinolone trovafloxacin has been associated with liver failure; sparfloxacin, gatifloxacin, and moxifloxacin can cause an abnormal heartbeat when taken in conjunction with tricyclic antidepressants or drugs to prevent cardiac arrhythmia.

We also knew that quinolones could cause joint aches and pains in about one percent of the population. But since the drug class was approved, it’s shown a far more disturbing side effect – tendonitis so severe that it leads to tendon rupture. According to the article, the FDA has received more than 1,000 reported cases of quinolones-related tendonitis. In most cases, the drug use was discontinued before it was too late. But when the patient continued to use the quinolone after the pain and swelling appeared, it sometimes led to tendon rupture. The reports suggest that older people and those taking steroids at the same time are most at risk. In some cases, the rupture occurred as late as 120 days after the patient stopped taking the drug.

As you can see, this article is not talking about minor side effects like nausea or a bad taste in the mouth. We’re talking about major effects that could disable or even kill you. There are four other drugs that were detailed in the journal article; more information is listed below.

These certainly weren’t the first drugs to exhibit serious side effects after they received FDA approval – and they won’t be the last. At HSI, we’ll do our best to stay on top of this information, and bring it to you as quickly as possible. You can also check for post-approval reports on your own, through the FDA’s MedWatch website (www.fda.gov/medwatch).

Please pass this information along to anyone you know who may take one of these medications. Everyone needs to know the risks of the drugs they’re taking – not just the doctors and pharmacists who prescribe and dispense them.


Elderly and diabetics at higher risk for complications from COX-2 inhibitors

COX-2 inhibitors, like the much-advertised Vioxx and Celebrex, are a new class of non-steroidal anti-inflammatory drugs (NSAIDs) designed to minimize gastrointestinal side effects. While COX-2 inhibitors do seem to cause fewer GI problems than traditional NSAIDs, the article shows that the drugs can cause other serious side effects in many people. For example, older patients, as well as those with heart failure, diabetes, cirrhosis, or dehydration, can experience reduced kidney function as a result of COX-2 inhibitors. As the article states, “The same caution used in prescribing traditional NSAIDs for patients at increased risk for renal toxicity (kidney poisoning) should be exercised in prescribing COX-2 inhibitors.” Also, people who are allergic to aspirin or traditional NSAIDs can still experience reactions to the new COX-2 inhibitor drugs.

Type II diabetes drugs can cause liver damage

Thiazolidinediones are a new drug class that helps improve glycemic control in Type II diabetes patients. One of the first drugs in this class, troglitazone, was withdrawn from the market in March of 2000 because it was linked with 61 liver failure deaths and seven liver transplants. Newer thiazolidinediones, like rosiglitazone (Avandia) and pioglitazone (Actos), were thought to be safer – but according to the article, they still pose a serious risk to patients with pre-existing liver problems.

Since their approval, there have been only two reported cases of liver failure from rosiglitazone and none from pioglitazone. But the article suggests that their improved safety record is not due to changes in the drug’s makeup, but rather increased screening and monitoring by prescribing doctors. People with previous signs of liver impairment should not take these drugs, and all people should be tested for pre-treatment levels of alanine transaminase before they begin taking them. (Alanine transaminase is an enzyme, high levels can indicate liver problems.) The article also recommends that patients taking these drugs have their alanine transaminase levels rechecked every two months during the first year of thiazolidinedione therapy, followed by periodic monitoring thereafter.

HIV drugs can cause life-threatening allergic reactions, ph imbalances, and more

 

 

Abacavir (known by the brand name Ziagen) is a drug used to treat infection with HIV, the virus believed to cause AIDS. But since its approval in 1998, there have been many reports of severe allergic reaction to the drug. New estimates indicate that two to five percent of patients treated with abacavir will exhibit the reaction. Signs of the allergy include rash, fever, malaise, fatigue, and nausea. Some patients also experience respiratory symptoms like coughing. The reaction usually occurs within the six weeks of beginning abacavir therapy.

Since its approval, abacavir has also been associated with a serious condition called lactic acidosis, an imbalance in the blood’s pH levels. Symptoms include weakness, nausea, abdominal pain, vomiting, and shortness of breath. Women seem to be at increased risk for this side effect, as well as people who are obese or have taken the drug for long periods of time.

Another HIV drug made the list, exhibiting similar side effects. Nevirapine (known by the brand name Viramune) can also cause serious allergic reactions. In trials during the approval process, nevirapine caused life-threatening skin reactions in nearly seven percent of treated patients. The drug can cause liver damage and ultimately, complete liver failure. These two side effects can occur together or separately. Most side effects were seen during the first six to eight weeks of therapy.

 

 

 

 

 

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.